RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the ...

the stringent testing the EU requires of pump manufacturers meant Tandem's product needed some time to catch up. Eli Lilly and Tandem teamed up to test the former's insulin product with the latter ...

To meet international guidelines, New Zealand needs to double the workforce that supports people with diabetes. Unless that ...

GAMMA Investing LLC increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 17.0% ...

Other makers of insulin pumps include Tandem Diabetes Care (TNDM) and Insulet (PODD).

RBC Capital Markets initiated coverage on Tandem Diabetes Care ... the rise of GLP-1s class drugs is not a major threat to insulin pump adoption. GLP-1 drugs such as Novo Nordisk A/S‘ (NYSE ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

Lyumjev -- an ultra-rapid acting insulin product. Although Lyumjev earned its approval in the 27-nation body back in 2020, the stringent testing the EU requires of pump manufacturers meant Tandem ...